TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS
Executive Summary
The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.
You may also be interested in...
Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL
Neither TG's UNITY-NHL nor Incyte's CITADEL-203 study reported any fatal adverse events - a problem for which Gilead and Verastem's PI3K inhibitors carry boxed warnings.
Novartis's Ofatumumab Pursues Entrenched Competitors In MS
Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.
Roche's Ocrevus: A Rare First-Year Blockbuster
Ocrevus generated roughly $935m in 2017 after launching in April, exceeding recent drug launches and putting the multiple sclerosis therapy in company with early successes like Opdivo, Ibrance, Tecfidera and Eylea.
Need a specific report? 1000+ reports available
Buy Reports